Oncotarget

Research Papers:

Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma

Jin Wang, Li Li, Bai-qiang Dong, Yu-jin Xu, Yuan-da Zheng, Zhong-wen Sun, Yang Yang, Yuan-Yuan Chen _, Xiao-zhong Chen and Ming Chen

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:27458-27467. https://doi.org/10.18632/oncotarget.8480

Metrics: PDF 1746 views  |   HTML 1853 views  |   ?  


Abstract

Jin Wang1,*, Li Li2,*, Bai-qiang Dong1, Yu-jin Xu1, Yuan-da Zheng1, Zhong-wen Sun3, Yang Yang1, Yuan-Yuan Chen1, Xiao-zhong Chen1, Ming Chen1

1Department of Radiation Oncology, Zhejiang Key Lab of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China

2Department of Ultrasonography, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China

3Department of Oncology, Jining First People’s Hospital, Jining, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Yuan-Yuan Chen, e-mail: [email protected]

Keywords: serum lactic dehydrogenase, intensity-modulated radiation therapy, nasopharyngeal carcinoma, prognostic factor, metastasis

Received: January 04, 2016     Accepted: March 18, 2016     Published: March 30, 2016

ABSTRACT

Purpose: To examine the function of serum lactic dehydrogenase (SLDH) level after intensity-modulated radiotherapy (IMRT) as a predictive factor for and loco-regional relapse free survival (LRFS), distant metastasis-free survival (DMFS), disease free survival (DFS), and overall survival(OS) among patients with in-situ nasopharyngeal carcinoma (NPC).

Results: Compared with the normal pt-SLDH group, elevated pt-SLDH demonstrated significant lower DMFS (46 versus 66 months, hazard ratio (HR) 4.07, 95% CI 2.43–6.80, p < 0.001), DFS (46 versus 63 months, HR 2.78, 95% CI 1.70–4.53, p < 0.001), and OS (54 versus 66 months, HR 2.93, 95% CI 1.65–5.23, p < 0.001). Distant metastasis were observed in 32.8% (20/61) patients with elevated pt-SLDH, and 8% (54/678) in normal SLDH (odds ratio (OR) 6.13, 95% CI 3.35–11.18, p < 0.001). COX regression showed that pt-SLDH was an independent prognostic factors for OS (HR 2.91, 95% CI 1.57–5.41, p < 0.001), DMFS (HR 4.21, 95% CI 2.51–7.07, p < 0.001), LRFS (HR 2.53, 95% CI 1.22–5.24, p < 0.001), and DFS (HR 2.81, 95% CI 1.72–4.59, p < 0.001).

Materials and Methods: The records of 739 in-situ NPC patients admitted to Zhejiang Cancer Hospital between January 2007 and May 2012 were retrospectively reviewed. The relationships between post-treatment SLDH (pt-SLDH) and LRFS, DMFS, DFS, and OS were analyzed.

Conclusions: Our finding indicated that elevated pt-SLDH could be a simple available prognostic indicator for distant metastasis and survival for in-situ NPC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8480